propafenone has been researched along with Dizzyness in 8 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 9.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| "The efficacy of propafenone in the treatment of paroxysmal atrial fibrillation was investigated in 16 patients presenting with frequent and/or poorly tolerated paroxysmal atrial fibrillation despite prophylactic treatment in 13 patients." | 7.68 | [Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation]. ( Bru, P; Cointe, R; Gerard, R; Lévy, S; Metge, M; Paganelli, F; Vrancea, F, 1993) |
| "Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone." | 7.67 | Propafenone for the treatment of severe ventricular arrhythmias. ( Bar-Shlomo, B; Boroomand-Rashti, K; Rabkin, SW; Rotem, CE, 1984) |
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 5.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| " Three months after starting citalopram, she experienced episodes of chest tightness and dizziness." | 3.74 | Adverse effects of propafenone after long-term therapy with the addition of citalopram. ( Garcia, A, 2008) |
| "The efficacy of propafenone in the treatment of paroxysmal atrial fibrillation was investigated in 16 patients presenting with frequent and/or poorly tolerated paroxysmal atrial fibrillation despite prophylactic treatment in 13 patients." | 3.68 | [Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation]. ( Bru, P; Cointe, R; Gerard, R; Lévy, S; Metge, M; Paganelli, F; Vrancea, F, 1993) |
| "Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone." | 3.67 | Propafenone for the treatment of severe ventricular arrhythmias. ( Bar-Shlomo, B; Boroomand-Rashti, K; Rabkin, SW; Rotem, CE, 1984) |
| "Two patients with recurrences of sustained VT in this group were later successfully treated with propafenone, 900 mg/day; overall, 8 of 9 patients with recurrences of sustained VT were successfully treated with 900 mg/day." | 1.27 | Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment. ( Ambrosioni, E; Bracchetti, D; Marchesini, B; Naccarella, F; Palmieri, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Garcia, A | 1 |
| Alexoudis, A | 1 |
| Spyridonidou, A | 1 |
| Pritchett, EL | 1 |
| Page, RL | 1 |
| Carlson, M | 1 |
| Undesser, K | 1 |
| Fava, G | 1 |
| Rabkin, SW | 1 |
| Rotem, CE | 1 |
| Boroomand-Rashti, K | 1 |
| Bar-Shlomo, B | 1 |
| Naccarella, F | 1 |
| Bracchetti, D | 1 |
| Palmieri, M | 1 |
| Marchesini, B | 1 |
| Ambrosioni, E | 1 |
| Cointe, R | 1 |
| Metge, M | 1 |
| Bru, P | 1 |
| Vrancea, F | 1 |
| Gerard, R | 1 |
| Paganelli, F | 1 |
| Lévy, S | 1 |
| Cai, WM | 1 |
| Chen, B | 1 |
| Cai, MH | 1 |
| Chen, Y | 1 |
| Zhang, YD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for propafenone and Dizzyness
| Article | Year |
|---|---|
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
2 trials available for propafenone and Dizzyness
| Article | Year |
|---|---|
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2003 |
The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Area Under Curve; China; Cytochrome P-450 CYP2D | 1999 |
5 other studies available for propafenone and Dizzyness
| Article | Year |
|---|---|
Adverse effects of propafenone after long-term therapy with the addition of citalopram.
Topics: Accidental Falls; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Dizzin | 2008 |
Images in emergency medicine. Reversible QRS complex widening after oral administration of propafenone.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Diagnosis, Differential; Dizziness; Electrocardiogr | 2010 |
Propafenone for the treatment of severe ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dizziness; Female; Humans; Male; Middle A | 1984 |
Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Dizziness; Female; Humans | 1984 |
[Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation].
Topics: Administration, Oral; Adolescent; Adult; Aged; Atrial Fibrillation; Dizziness; Drug Evaluation; Fema | 1993 |